ALKERMES | ALKS - Current Liabilities


ALKERMES reported $599.5M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
ALKERMES USD 599.5M 56.06M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Malin Corporation EUR 1000K 500K Dec/2024
Merck USD 26.94B 1.38B Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Otsuka Holdings JPY 686.12B 63B Mar/2026
Ovoca Bio EUR 186K 2.26M Jun/2025
Pfizer USD 34.35B 2.64B Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026